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Abstract
Background: Endometrial stromal sarcoma (ESS) is a rare disease with probably less than 700 new
cases in the USA or Europe per year. The aim of this study was to evaluate the behavior of low-
grade endometrial stromal sarcoma (LGESS) in relation to their clinical and pathological features
and to identify possible prognostic factors.
Patients and methods: Fourteen patients with histologically proven ESS were included in the
analysis. Endometrial stromal sarcoma is characterized by proliferations composed of cells with
Endometrial stromal cell differentiation. Low-grade endometrial stromal sarcoma has an infiltrating
margin and typically show extensive worm-like vessel invasion.
Results: The median age was 44.35 ± 6 years. The most common presenting symptom was vaginal
bleeding, occurring in twelve patients (86%). Diagnosis was made through Fractional dilatation and
curettage in four patients (28.5%). Eight patients had a total abdominal hysterectomy and salpingo-
ophorectomy (57%). Radiotherapy as adjuvant therapy was administered to four patients (28.5%).
The median follow-up time was 45.6 months (range 24–84). The median overall survival of the 14
patients was 45.35 ± 21 months (range 20–83). Three of 14 patients demonstrated a recurrence
of disease at 9, 72, and 96 months respectively. The recurrent diseases were treated with surgery,
chemotherapy, and radiotherapy. No patient died of the disease. Clinico-pathological parameters
did not significantly differ between patients with and without recurrence, but patients with no
myometrial invasion and low mitotic count <= 5/HPF showed longer disease-free survival.
Conclusion: Five-year survival rate was 93%. Survival probabilities were calculated by the product
limit method of Kaplan and Meier that showed, patients with no myometrial invasion and low
mitotic count <= 5/HPF have longer disease-free survival, but P value was not significant.
Background
Endometrial Stromal Sarcomas (ESSs) are very rare malig-
nant tumors that constitute approximately 10% of all
uterine sarcomas but only around 0.2% of all uterine
malignancies [1]. The annual incidence of ESS is 1–2 per
million women accounting for 400 to 700 new cases each
year in Europe [2].
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tion may be difficult, and the diagnosis is often made
postoperatively after histological examination [3,4]. The
typical gross appearances of ESS are a single nodule, mul-
tiple solid-cystic masses, and a poorly demarcated lesion
with occasional cystic degeneration or rarely cystic multi-
locular lesion [5]. There are three types of endometrial
stromal tumors: endometrial stromal nodule, low-grade
ESS (LGESS), and high-grade ESS (HGESS). Only the
nature of the margin, histologically differentiate LGESS
from stromal nodule. The division of endometrial stromal
sarcomas into low-grade and high-grade categories has
fallen out of favor, and the term endometrial stromal sar-
comas now considered best restricted to neoplasms that
were formally to as low-grade endometrial stromal sarco-
mas [6]. High-grade tumors without recognizable evi-
dence of a definite endometrial stromal phenotype are
now termed endometrial sarcomas [7].
The pathogenesis of these lesions remains unknown, but
exposure to tamoxifen and unopposed estrogens has been
implicated in some cases [8].
Uterine sarcomas most often affect postmenopausal
women [9]. Women with LGESS are younger than women
with other uterine sarcomas, with a median age between
45 and 57 years and, generally do not have the usual risk
factors for endometrial cancer. Symptoms at presentation
include abnormal vaginal bleeding, progressive menor-
rhagia, and abdominal pain. While often indolent in
behavior, ESS is malignant, and up to 30% of women with
low-grade ESS have extra uterine disease at presentation.
Surgery is fundamental in LGESS as other sarcoma. Man-
agement and treatment generally consists of total abdom-
inal hysterectomy and bilateral salpingo-oophorectomy.
Due to the high recurrence risk even with localized
tumors, many clinicians advocate use of adjuvant chemo-
therapy, radiation therapy, and/or hormone therapy to
suppress tumor growth [4]. There is no firm evidence from
a prospective study that adjuvant chemotherapy or radia-
tion therapy is of substantial benefit for patients with uter-
ine sarcoma. Postoperative pelvic radiotherapy reduces
local recurrence but has not been consistently shown to
prolong survival.
Progestin therapy has been reported to reduce the risk of
recurrence when used in the adjuvant setting. Most
women with LGESS undergo bilateral salpingo-oophorec-
tomy as part of primary treatment but estrogen also can be
produced by extraovarian sources.
These tumors typically have an indolent growth with a
tendency for late recurrence [6]. Pelvic or abdominal
recurrences in stage I disease develop in one-third to one-
half of patients [10].
The aim of this study was to evaluate the clinical outcome
and the behavior of LGESS in relation to its clinical and
pathological features.
Patients and methods
This study includes 14 patients with histologically proven
low-grade endometrial stromal sarcoma treated at of
Gynecologic Oncology Department of the Vali-Asr Uni-
versity Hospital, Tehran, Iran, between 1999 to 2005.
Hospital records and available histological material for
each patient were reviewed retrospectively. Slides from
each patient were reexamined to confirm the diagnosis.
Patients with a diagnosis of high-grade endometrial stro-
mal sarcoma were not included. Demographic informa-
tion, pathologic, and treatment information were
collected from the clinic and hospital charts. All had pri-
mary surgical management. Eight patients underwent
total abdominal hysterectomy and salpingo-oophorec-
tomy, and three patients underwent subtotal hysterec-
tomy and salpingo-oophorectomy. In one patient,
subtotal hysterectomy without salpingo-oophorectomy
was performed. They had regular follow-up visits until the
end of study.
The end point of 5-year survival was used for analysis. Sur-
vival probabilities were calculated by Kaplan and Meier
method. Correlation between recurrence and clinico-
pathological parameters (myometrial invasion, mitotic
count) was tested using the Fisher Exact test. P values of
less than 0.05 were considered statistically significant.
Results
Fourteen patients with LGESS were identified at our insti-
tution from 1999 to 2005. The median age was 44.35 ± 6
years (range 33–52). The mean parity of the patients was
4.4 (range 0–8). The most common presenting symptom
was vaginal bleeding, occurring in twelve patients(86%)
while other features such as pelvic mass and acute abdom-
inal pain were observed in 1 (7%) and 1 (7%) patients,
respectively (table 1). Clinical impression in four patients
(29%) was uterine myoma.
Fractional dilatation and curettage (FD&C) was per-
formed in four patients presenting with abnormal uterine
bleeding (AUB). Diagnosis was made through FD&C in
four patients. The other 10 patients were diagnosed by
hysterectomy. All the histological slides were reexamined
by the same pathologist.
Eight patients had a total abdominal hysterectomy and
four patients had a subtotal hysterectomy as part of theirPage 2 of 5
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lectomy following the previous subtotal hysterectomy.
Radiotherapy as adjuvant therapy was administered to
four patients (29%).
The median follow-up time was 45.6 months (range 24–
84). Five-year survival rate was 93%. The median overall
survival of the 14 patients was 45.35 ± 21 months (range
20–83). Only one patient recurred at 9 months. Two of 14
patients demonstrated a recurrence of disease at 6 years,
and 8 years respectively (table 2). Recurrent disease in pel-
vic was treated by combination chemotherapy and surgery
in one patient. The second patient with recurrence in pel-
vic and lung received combination chemotherapy and
external radiotherapy. In the third patient, recurrence in
vagina and lung was treated with combination chemo-
therapy only. No patient died of the disease. Twelve
patients are alive without disease and two alive with dis-
ease.
Five-year survival rate was93%. Survival probabilities
were calculated by the product limit method of Kaplan
and Meier that showed, patients with no myometrial inva-
sion and low mitotic count <= 5/HPF have longer disease-
free survival (fig 1 and fig 2), but P value was not signifi-
cant.
Discussion
ESS are very rare malignant tumors that make up approx-
imately 10% of all uterine sarcomas but only around
0.2% of all uterine malignancies [11].
ESS are divided in low and high-grade tumors according
to cell morphology and mitotic count [6], Boardman CH,
et al defined low-grade ESS from high-grade ESS by the
cellular uniformity, less frequent mitosis (<3 per 10 high-
power fields versus >10), and lack of hemorrhage and
necrosis [3]. However, there are controversies surround-
ing the separation of endometrial stromal sarcomas into
high and low grade based on mitotic activity [12]and at
present, mitotic counts are no longer used to differenti-
ated high-grade from low-grade lesions [7]. Accordingly,
several authors have concluded that two separate disease
entities exist and, respectively, that HGESS should be
regarded as an undifferentiated sarcoma or as a unique
Table 2: Recurrent Cases
No of patients Disease-Free survival Sites of recurrence Treatment of Recurrence
Chemotherapy Irradiation surgery
6 9 months Pelvic and lung Yes(first) Yes No
7 8 years Vagina and lung Yes No No
8 6 years pelvic Yes No Yes(first)
Table 1: patient characteristics.
No Age Parity Symptom D&C Type of Operation Myometrial Invasion Mytotic Count Irradiation Recurrence
1 49 2 AUB Yes TAH&BSO Low =<5/10HPF Yes
2 42 6 AUB Yes TAH&BSO Deep >5/10HPF Yes
3 51 3 AUB No TAH&RSO No =<5/10HPF Yes
4 52 5 AUB No TAH&RSO >5/10HPF No
5 38 7 AUB Yes
6 37 3 Pelvic Mass No Trachelectomy & RSO No =<5/10HPF Yes Yes
7 48 8 AUB No TAH No Yes
8 33 5 AUB No TAH&BSO No >5/10HPF No Yes
9 44 Virgin AUB No TAH&BSO No
10 48 3 AUB No subTAH&BSO No =<5/10HPF No
11 38 4 Acute Abdomen No subTAH No
12 50 1 AUB No subTAH&BSO No =<5/10HPF No
13 48 8 AUB Yes TAH&BSO Low =<5/10HPF No
14 43 7 AUB No subTAH&BSO No =<5/10HPF No
AUB: Abnormal uterine bleeding; TAH: total abdominal hysterectomy; HPF: high power field; BSO: Bilateral salpingooopherectomy; RSO: Residual 
salpingooopherectomyPage 3 of 5
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without any detectable carcinoma portion) [13].
Low-grade endometrial stromal sarcoma (LGESS) has an
infiltrating margin and typically shows extensive worm-
like vessel invasion [6].
Most patients are in the age range of 42 to 53 years. More
than half the patients are premenopausal. Young women
and girls may be affected. In this study, 79% of patients
were premenopausal.
Abnormal vaginal bleeding is the most common present-
ing symptom, and abdominal pain and uterine enlarge-
ment may occur [9,7]. We showed abnormal vaginal
bleeding in 86% of the patients. Clinical impression in
four cases was uterine myoma (28.5%) and one patient
had presented with severe abdominal pain.
The median follow-up time was 45.6 months (range 24–
84). Five-year survival rate was 93%. In this study, the
median overall survival of the 14 patients was 45.35 ± 21
months (range 20–83).
Although the bulk of the tumor is almost always intramy-
ometrial [14], most endometrial stromal sarcomas
involve the endometrium, and uterine curettage usually
leads to diagnosis [7]. In our study, the diagnosis in four
patients (28.5%) was made through D&C. The other 10
patients were diagnosed by hysterectomy (71%). Surgery
has always been described as the most effective treatment
in LGESS as other uterine sarcomas. Primary surgery was
performed in 13 patients in our series. The one patient
refused from any treatment such as surgery.
The efficacy of adjuvant therapy in patients with ESS is
still not proven [15]. In our study radiotherapy as adju-
vant, therapy was administered to four patients (28.5%),
but one of them recurred at 9 months.
Although LGESS behavior is relatively indolent, late recur-
rence and distant metastases may occur [14]. The risk of
recurrence is thought to be as high as 50%, although these
tumors are usually slow growing and recurrences occur
late. In one large series, the interval before recurrence var-
ied from 3 months to 23 years, with a median interval of
3 years. In the largest clinico-pathologic study to date on
ESS, the median time between hysterectomy and relapse
was 5.4 years and 9 month for stages 1 and 3–4, respec-
tively [16]. We showed only one recurrence at 9 months,
but two recurrences occurred at 6 and 8 years respectively.
In Brunisholza study, the recurrent disease mainly spread
to the pelvis, lower genital tract, lungs, and rarely to other
site [17]. Recurrence sites in our patients were vagina, pel-
vis, and lung.
Prolonged survival and even cure are common after surgi-
cal resection of recurrent or matastatic lesions [7]. One of
our patients is alive 3 years without disease after resection
of vaginal metastasis and chemotherapy.
Uterine sarcomas have a poor prognosis, and survival is
much worse than that reported for endometrial adenocar-
cinoma, with an overall survival of less than 50% at 2
years, even when presenting at an early stage [18]. A
higher survival probability for patients with LGESS com-
pared to other uterine sarcoma is often reported [19]. In
this study, five-year survival rate was 93%.
Survival of patients with LGESS based on number of mitosisFigure 2
Survival of patients with LGESS based on number of mitosis.
Survival of patients with LGESS based on myometrial invasionFigure 1
Survival of patients with LGESS based on myometrial inva-
sion.Page 4 of 5
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Prognostic factors in patients with ESS are still discussed
controversially [11]. The negative prognostic influence of
a high mitotic count was revealed in previous studies [20].
In the present study, survival probabilities were calculated
by the product limit method of Kaplan and Meier that
showed, patients with no myometrial invasion and low
mitotic count <= 5/HPF have longer disease-free survival,
but P value was not significant.
Conclusion
In summary, we found not significant association
between mitotic count, myometrial invasion and risk of
recurrence. The large variation in pathologic characteris-
tics and in treatment policies, combined with the scarcity
of patients, has meant that in the past, there has been a
general feeling that there is insufficient information on
optimal managements and their influence on tumor
behavior. The difficulty in obtaining information on
tumor behavior and best treatment has led different
authors to study of the prognostic factors. Additional
studies on a larger group of patients allowing multi anal-
ysis are necessary to be better able to predict the prognosis
of patients with ESS and to define the exact role of adju-
vant therapy.
Competing interests
The author(s) declare that they have no competing inter-
est
Authors' contributions
TAG participated in the design of the study and partici-
pated in drafting the manuscript.
NB carried out the surgery and helped to draft the manu-
script.
MS participated in drafting the manuscript.
AM carried out the chemotherapy and follow-ups.
All authors read and approved the final manuscript.
References
1. Boardman CH, Webb MJ, Jefferies JA: Low-Grade Endometrial
Stromal Sarcoma of the Ectocervix after Therapy for Breast
Cancer.  Gynecologic Oncology 2000, 79:120-123.
2. Pink D, Lindner T, Mrozek A, Kretzschmar A, Thuss-Patience PC,
Dörken B, Peter Reichardt : Harm or benefit of hormonal treat-
ment in metastatic low-grade endometrial stromal sarcoma:
Single center experience with 10 cases and review of the lit-
erature.  Gynecol Oncol 2006, 101:464-469.
3. Mesia AF, Demopoulos I: Effects of leuprolide acetate on low-
grade endometrial stromal sarcoma.  Am J Obstet Gynecol 2000,
182:1140-1141.
4. Husseiny GE, Bareedy NA, Mourad WA, Mohamed G, Shoukri M,
Subhi J: Prognostic factors and treatment modalities in uter-
ine sarcoma.  Am J Clin Oncol 2002, 25:256-260.
5. Pekindil G, Tuncyurek O, Orguc S, Inceboz U, Kandiloglu AR, Caglar
H: A case of endometrial stromal sarcoma with curvilinear
calcification.  Gynecologic Oncology 2005, 98:318-321.
6. Shafi M, Luesley DM, Jordan JA: Gynecological Oncology Churchil Living-
stone, UK; 2001:120-121. 
7. Berkowitz RS, Goldstein DP: Uterine cancer.  In Practical Gyneco-
logic Oncology 4th edition. Edited by: Berek JS, Hacker NE. Williams &
Wilkins; 2005:431-432. 
8. Feeley KM, Burton JL, Wells M: A diagnostic approach to
endometrial biopsies: selected topics.  Current Diagnostic Pathol-
ogy 2000, 6:13-20.
9. Livi L, Paiar F, Shah N, Blake P, Villanucci A, Amunni G: Uterine sar-
coma: twenty-seven years of experience.  Int J Radiat Oncol, Biol,
Phys 2003, 57:1366-1373.
10. Spano JP, Soria JC, Kambouchner M, Piperno-Neuman S, Morin F,
Morere JF, Martin A, Breau JL: Long term survival of patients
given hormonal therapy for metastatic endometrial stromal
sarcoma.  Med Oncol 2003, 20:87-93.
11. Liokumovich P, Goldberg I, Davidson B, Gotlieb WH, Zahavi T, Ben-
baruch G, Kopolovic J: Expresion of metalloproteinases
endometrial stromal sarcoma: immunohistochemical study
using image analysis.  J Clin Pathol 1999, 52:198-202.
12. Fadare O, McCalip B, Rajan Mariappan R, Hileeto D, Parkash V: An
endometrial stromal tumor with osteoclast-like giant
cells:Expanding the morphological spectrum.  Ann Diag Pathol
2005, 9:160-165.
13. Amant F, Vergote I, Moerman P: The classification of a uterine
sarcoma as high-grade endometrial stromal sarcoma_
should be abandoned.  Gynecol Oncol 2004, 95:412-413.
14. Stadsvold JL, Molpus KL, Baker JJ, Michael K, Remmenga SW: Case
Report-Conservative management of a myxoid endometrial
stromal sarcoma in a 16-year-old nulliparous woman.  Gynecol
Oncol 2005, 99:243-245.
15. Gellera MA, Argentaa P, Bradleya W, Dusenberyb KE, Brookera D,
Downs LS, Judsona PL, Carsona LF, Boentea MP: Treatment and
recurrence patterns in endometrial stromal sarcomas and
the relation to c-kit _expression.  Gynecol Oncol 2004,
95:632-636.
16. Amant F, Moerman P, Cadron I, Neven P, Berteloot P, Vergote I: The
diagnostic problem of endometrial stromal sarcoma:report
on six cases.  Gynecol Oncol 2003, 90:37-43.
17. Brunisholza YJ, Scurryb MJ, Proietto A: Case Report-Endometrial
stromal sarcoma resembling adenomyosis and menstrual-
phase endometrium.  Gynecol Oncol 2004, 95:256-259.
18. Rovirosa A, Ascaso , Ordi J, Abellana , Arenas M, Lejarcegui JA, Pahisa
J, Puig-Tintore LM, Mellado B, Armenteros B, Iglesias X, Biete A: Is
vascular and lymphatic space invasion a main prognostic fac-
tor in uterine neoplasms with a sarcomatous component? A
retrospective study of prognostic factors of 60 patients strat-
ified by stages.  Int J Radiation Oncol Biol Phys 2002, 52:1320-1329.
19. Nardal RR, Kjoerstad K, Stenwing AE, Trope CT: Leimyosarcoma
(LMS) and endometrial stromal sarcoma (ESS) of the
uterus: a survey of patients treated at the norvegian Radium
Hospital 1971–1985.  Int J Gynecol Cancer 1993, 3:110-115.
20. Bonder K, Bonder-Alder B, Obermair A, Windbichler G, Petru E,
Mayerhofer S, Czerwenka K, Leodolter S, Kainz C, Mayerhofer K:
Prognostic parameters in endometrial stromal sarcoma: A
clinicopathological study in 31 patients.  Gynecol Oncol 2001,
81:160-165.Page 5 of 5
(page number not for citation purposes)
